Herpangina Treatment Market Forecast Signals New Revenue Opportunities Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Herpangina Treatment Market Growth Potential: How Will Market Size Change Through 2030?
The herpangina treatment market has posted substantial growth in recent years, with projections indicating a rise from $1.96 billion in 2025 to $2.1 billion in 2026, representing a compound annual growth rate (CAGR) of 7.1%. This expansion during the historical period has been driven by factors such as heightened prevalence of viral infections in pediatric populations, absence of specialized antiviral therapies, increased focus on children’s healthcare education, frequent seasonal disease outbreaks, and persistent limitations in healthcare access within rural regions.
The herpangina treatment market is projected to experience robust expansion over the coming years, reaching a valuation of $2.87 billion by 2030, with a compound annual growth rate (CAGR) of 8.1%. This anticipated growth during the forecast period is driven by the increasing use of telehealth services, advancements in pain management approaches, a shift toward home-based care, the creation of child-friendly drug formulations, and the rising consumption of over-the-counter (OTC) medications. Key trends shaping this period include the emergence of pediatric telemedicine services, the development of formulations aimed at symptom relief, greater public awareness about managing viral infections, the integration of homecare monitoring technologies, and an expanding market for OTC pain relief products.
Download A Free Sample Report For Comprehensive Market Insights:
Herpangina Treatment Market Demand Drivers Creating New Revenue Opportunities
The growth of the herpangina treatment market is anticipated to be driven by a rise in research and development efforts moving forward. Herpangina, a viral condition commonly affecting children, results in painful sores or ulcers on the tonsils and the back of the throat, triggered by coxsackievirus and enteroviruses. Treatment for herpangina aims to alleviate symptoms like blisters, high fever, oral or throat discomfort, drooling, and appetite loss. As an example, the Center for Drug Evaluation and Research (CDER), a division of the U.S. Food and Drug Administration (FDA), reported in January 2024 through its New Drug Therapy Approvals 2023 report that 55 novel drugs were approved in 2023, with 20 (36%) classified as first-in-class, compared to 37 novel drug approvals in 2022. Consequently, the increase in research and development activities is fueling the expansion of the herpangina treatment market.
A growing pediatric population is expected to stimulate the herpangina treatment market’s expansion moving forward. The pediatric population includes young individuals from birth through adolescence or up to the age of maturity. Managing herpangina in this group often involves symptom control, supportive care, and maintaining proper hydration. For instance, the Federal Interagency Forum on Child and Family Statistics, a coalition of 23 U.S. federal agencies involved in child and family research, noted in December 2024 that with 72.5 million children in the United States in 2022, this number is projected to reach 78.2 million by 2050, indicating a sustained upward trajectory. Thus, the rising pediatric population is propelling the herpangina treatment market forward.
Escalating healthcare expenditure is projected to boost the herpangina treatment market’s growth in the coming period. Health expenditure encompasses all costs linked to delivering health services, nutrition programs, family planning initiatives, and emergency aid designated for health. Higher healthcare spending can improve herpangina treatment by increasing the availability of skilled healthcare professionals and resources. For example, the Centers for Medicare & Medicaid Services (CMS), a U.S. federal agency, reported in June 2025 that National Health Expenditure (NHE) rose by 7.5% to $4.9 trillion in 2023, equivalent to $14,570 per person, representing 17.6% of Gross Domestic Product (GDP). Hospital expenditures climbed 10.4% to $1,519.7 billion in 2023, outpacing the 3.2% increase seen in 2022. Therefore, rising healthcare expenditure is driving the herpangina treatment market’s growth.
Herpangina Treatment Market Segment Landscape: Which Areas Lead Market Development?
The herpangina treatment market covered in this report is segmented –
1) By Treatment: Topical Anesthetics, Ibuprofen Or Acetaminophen, Other Treatments
2) By Virus: Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus
3) By Symptoms: High Fever, Sore Throat, Blisters Or Ulcers In The Throat Mouth, Difficulty Swallowing, Loss Of Appetite, Neck Pain, Swollen Lymph Glands, and Headache
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Herpangina Treatment Market Industry Leaders And Market Competition
Major companies operating in the herpangina treatment market are Cipla Inc., Dr. Reddys Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Aurobindo Pharma Ltd., Lupin Limited, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Mucocort, Aurena Laboratories AB, CSL Limited, Bayer AG, Sanofi, Johnson & Johnson, Novartis AG, GlaxoSmithKline Plc, Boehringer Ingelheim International GmbH, Pfizer Inc, Eli Lilly and Company
Access The Complete Herpangina Treatment Market Report:
Herpangina Treatment Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the global herpangina treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpangina treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
